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Abstract
There is increasing amount of evidence for sex variation in drug efficiency and toxicity pro-
files. Women are more susceptible than men to acute liver injury from xenobiotics. In gener-
al, this is attributed to sex differences at a physiological level as well as differences in
pharmacokinetics and pharmacodynamics, but neither of these can give a sufficient expla-
nation for the diverse responses to xenobiotics. Existing data are mainly based on animal
models and limited data exist on in vitro sex differences relevant to humans. To date, male
and female human hepatocytes have not yet been compared in terms of their responses to
hepatotoxic drugs. We investigated whether sex-specific differences in acute hepatotoxicity
can be observed in vitro by comparing hepatotoxic drug effects in male and female primary
human hepatocytes. Significant sex-related differences were found for certain parameters
and individual drugs, showing an overall higher sensitivity of female primary hepatocytes to
hepatotoxicants. Moreover, our work demonstrated that high content screening is feasible
with pooled primary human hepatocytes in suspension.
Introduction
There are marked sex-based differences in the epidemiology, clinical manifestations, progression
and treatment of disease, as well as pharmacodynamics, -kinetics, and adverse drug effects.
These differences are derived from the fundamental biological differences between sexes and are
only partially understood in molecular and cellular terms [1]. Females are under-represented in
basic research as well as in animal tests, and more importantly, in human clinical trials. For
many years, the Food and Drug Administration (FDA) guidelines specifically precluded partici-
pation of females in many drug studies [2] [3]. Laboratory animals are predominantly male [4],
even in studies of diseases that disproportionately affect more women. Males are preferred be-
cause they are thought to be less variable due to their constant hormone levels. This variability
should not be ignored as hormones can play a role in many inflammatory responses [5] [6].
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Though there is considerable evidence for sex differences at all levels of biological organisation,
experimental test results taken frommales are assumed to be equally applicable to females [7]
[8] [9] [10].
Currently, the sex of experimental animals or cells is not regularly reported in scientific pub-
lications. Overall less than 40% of studies using experimental animals and only about 25% of
studies using cells in culture indicate the sex of the experimental material [11] [12].
In 2012, the American Physiological Society (APS) was one of the first bodies within the sci-
entific publication community to announce that sex indication of the experimental material,
derived from animals or humans, is required for publication in their journals [11]. This is an
example of the increasing awareness on the importance of considering sex differences in drug
development and preclinical studies [13]. The NIH also plans to address the issue of sex and
gender inclusion across biomedical research multi-dimensionally, pointing out the need to in-
dicate the sex of cell lines studied in vitro [14] and has launched a formal Request for Informa-
tion (RFI) from the research community: consideration of sex as a biological variable in
biomedical research.
In 2011, the European Commission established an expert group, called ‘Innovation
Through Gender’, with the aim to conduct a comprehensive review on how gender analysis
contributes to research. The group looked at concrete examples where appropriate treatment
of gender differences enhances research and, in their report, emphasised the importance of not
only studying sex differences in animal models, but also understanding sex differences in cell-
based research [15].
It is important to note that "Sex" refers to the biological and physiological characteristics
that define men and women, while "Gender" refers to the socially constructed roles, behaviours,
activities, and attributes that a given society considers appropriate for men and women [16].
However the term gender is incorrectly becoming more commonly used in scientific publica-
tions to describe biological variation traditionally assigned to sex because scientists are not
aware that a distinction exists between these terms and that this difference is an important one
[17].
Clinically, women have been reported to have a 1.5–1.7 fold greater risk than men of
experiencing an adverse drug reaction (ADR). Despite these reports on sex-based differences
in ADR for marketed substances, the evaluation of sex differences in efficacy and toxicity has
not been fully instituted for new drugs in development [18] [19]. Moreover, current in vitro
toxicological screening of chemicals and drugs should address sex differences [20].
Specifically, acute liver failure is a rare but very serious ADR that occurs more frequently in
women. In the United States, 74% of drug-induced acute liver failure occurs in women [21]
[22] and the case fatality rate is about 80% [21]. Establishing more adequate drug doses on
women may serve as a prevention method in the future.
The role of pharmacokinetics vs. pharmacodynamics is unclear, as is the impact of pharma-
cogenetics on both [23]. There are numerous theories why women experience more adverse
drug reactions than men (Table 1) [24] [2] [25]. None of these theories has proven to be valid
to sufficiently explain sex differences. Although gastrointestinal motility and metabolising en-
zymes vary by sex, studies have not consistently shown differences in drug bioavailability be-
tween men and women. The sex-based difference in plasma protein binding is postulated as a
contributor to different pharmacokinetics, but the extent of this contribution has not yet been
precisely defined in humans [18]. Age and number of prescribed drugs have not been con-
firmed as confounding factors to explain the higher incidence of ADRs among females. In
these studies, females were generally similar to males with respect to age and were almost iden-
tical with respect to the number of drugs prescribed [26]. Furthermore, reporting bias does not
seem to be a major factor in explaining why women experience more adverse events than men
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[21]. At the molecular level, many studies have reported sex differences in gene expression,
protein product, or enzyme activity for cytochrome P450 and transferases without showing a
clear distinct pattern [2] [27].
Sex-based differences are also important for organ and cell transplants. Sex mismatch in
liver transplantation increases the likelihood of graft failure, with female donor-male recipients
at greatest risk [28] [29] [30] [31]. In contrast, donor sex does not affect liver transplantation
outcome in children [32]. Stem cells transplants are the subject of intense studies in animal
models and in clinical trials. Some animal data suggest that male and female mesenchymal
stem cells may be very different [28]. Stem cell research using sex as a variable has revealed sex
differences in the properties of some adult stem cells. Findings include differences in mesen-
chymal stem cell activation and regenerative capacity of muscle-derived stem cells [15].
The presence of an XX or XY chromosomal complement is fundamental to the genome of
an individual person, animal, tissue, or cell. Every cell has a sex [33]. Therefore, based upon ex-
isting knowledge, it is inappropriate to assume that results from studies conducted on only one
sex apply to the other [11]. The biological mechanisms for the greater susceptibility of women
to drug-induced liver injury are still unknown.
Table 1. Why women experiencemore adverse drug reactions thanmen?
Factors Explanation as to why women experience more adverse drug
reactions than men
Psychosocial and lifestyle factors
[85][21]
Women take more medications than men and therefore have a
higher chance of experiencing side-effects and drug-drug-
interactions.
Women report adverse events more often than men (reporting
bias).
Women are exposed in different ways to men (e.g. occupation or
diet).
Differences in pharmacokinetics [86]
[18][62][87][88]
Dose recommendations are not sex-specific and women therefore
are often overdosed.
Bioavailability might be different due to different absorption and
gastrointestinal motility.
Tissue distribution is different because of different body
composition (variations in body-weight, amount of fat, plasma
volume), organ blood flow and plasma protein binding.
Differences in metabolism (there is no firm evidence and conflicting
data on varying levels of cytochrome P450 expression and activity,
as well as Phase II glucuronidation rate). Despite the large
variations in drug metabolism in individuals, correcting for height,
weight, surface area and body composition eliminates most “sex-
dependent” differences.
Elimination rates might be different (depending on the renal
excretion rates).
Differences in pharmacodynamics
[18][62][86]
Differences in drug targets.
Membrane phenomena (differences in membrane transport).
Receptor phenomena (differences in receptor numbers and
receptor binding).
Different interactions with macromolecules.
Differences in hormones [85][89] Influence of sex hormones, especially estrogen-effects.
Differences in the growth hormone secretion pattern (pulsatile in
male and continuous in females) from the pituitary gland with
consecutive different gene-regulation.
doi:10.1371/journal.pone.0122786.t001
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Data on cellular sex differences are limited and are mainly based on animal studies. To our
knowledge, the effect of known hepatotoxic drugs on primary human hepatocytes of both
sexes have not been compared yet in a systematic manner. The objective of this study was to in-
vestigate whether sex-specific differences in acute hepatotoxicity can be observed at a cellular
level by comparing the effects of well-known hepatotoxic drugs on male and female primary
human hepatocytes pooled from different donor groups.
Materials and Methods
Chemicals and supplies
Male, premenopausal female, and postmenopausal female cryopreserved human hepatocytes,
derived from 12 donors per group, were obtained from Kaly-Cell (Illkirch, France; Kaly-Cell
has been authorised by the French Ministry of Higher Education and Research (Ministère de
l'Enseignement supérieur et de la Recherche) to prepare and conserve human cells for scientific
use according article R1243-68 of the Public Health Code. This authorisation has been renewed
on 1st of September 2014; decision number AC 2014–2155) and stored in liquid nitrogen.
KLC-Thawing medium and KLC-Washing medium were purchased from Kaly-Cell. Tissue
culture treated, clear bottom black and white polystyrene 96 well plates were from Corning
(Pero, Italy). Trypan Blue was purchased from Invitrogen (San Giuliano Milanese, Italy).
Diclofenac sodium salt (CAS No. 15307-79-6), Chlorpromazine hydrochloride (CAS No. 69-
09-0), Verapamil hydrochloride (CAS No. 152-11-4), Acetaminophen (CAS No. 103-90-2),
Omeprazole (CAS No. 73590-58-6), and Caffeine (CAS No. 58-08-2) were purchased from
Sigma-Aldrich (Milan, Italy). For cell viability, the CellTiter-Glo luminescent assay (Promega,
Milan, Italy) was used. Fluorescence staining was performed with Hoechst 33342 (Invitrogen),
DHE (Sigma-Aldrich), TOTO3 (Invitrogen), TMRE (Sigma-Aldrich), Fluo-4 (Invitrogen), and
ER tracker Red (Invitrogen) dyes.
Cell culture and treatment
Three groups of cryopreserved human pooled hepatocytes were used: 3F (18–45 year old fe-
male), 4F (57–74 year old females), and M (20–82 year old males). The hepatocytes were
thawed following a standard procedure and counted using the Trypan blue exclusion method.
The cells were seeded in 96 well plates at a density of 5000 cells/well using the Hamilton Starlet
automated platform. Each group of pooled primary hepatocytes was exposed to 6 chemicals
(Diclofenac, Chlorpromazine, Verapamil, Acetaminophen, Omeprazole, and Caffeine) at 8 in-
creasing concentrations using a dilution factor 1:2 to cover a broad concentration range. The
highest used concentration of each chemical corresponds to the highest soluble dose of the
same chemical in culture medium. To assess the cell viability, pooled primary hepatocytes were
incubated at 37°C, 5% CO2, 100% humidity for 30 min, 2h, and 5h. For hepatotoxicity end-
points, the cells were exposed to the same chemicals and concentrations for 30 min, 1h, 2h, 3h,
4h, and 5h. All chemicals were solubilised in culture medium. In each plate, 8 untreated wells
per group were included. Three experimental replicates were tested. Cells treatment with drugs
was completely automated and the entire process was managed by Hamilton Software (Agrate
Brianza, Italy).
Viability assay
CellTiter-Glo luminescent cell viability assay (Promega) was used to measure cell viability.
Briefly, primary pooled hepatocytes were seeded in 96 well white plates and were exposed to 6
chemicals (Diclofenac, Chlorpromazine, Verapamil, Acetaminophen, Omeprazole, and
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Caffeine) across 8 concentrations for 30 min, 2h, and 5h. Cells were lysed with a volume of
CellTiter-Glo Reagent equal to the volume of cell culture medium present in the well. After
mixing the content for 2 min on a shaker, plates were incubated for 10 min at room tempera-
ture and luminescence was measured using a BMGmicroplate reader (BMG Labtech, Pero,
Italy).
High Content Analysis
Primary pooled hepatocytes were seeded in 96 well clear bottom black plates and were exposed
to 6 chemicals (Diclofenac, Chlorpromazine, Verapamil, Acetaminophen, Omeprazole, and
Caffeine) across 8 concentrations for 30 min, 1h, 2h, 3h, 4h, and 5h. In order to capture the
mechanisms of toxicity, cells exposed to chemicals for 30 min and 3h were stained with dihy-
droethidium (DHE). Hepatocytes treated for 1h and 3h were stained with tetramethylrhoda-
mine (TMRE) and TOTO3 dyes. 2h and 4h treated cells were stained with ER tracker red.
Calcium accumulation was instead measured within cells exposed to chemicals for 5h and
stained with Fluo-4. All the staining were performed in untreated and treated hepatocytes di-
luting each dye in growth media in presence of Hoechst 33342. After 30 min incubation with
each dye at 37°C, 5% CO2 (according to supplier's instructions), and 100% humidity, live cells
were imaged using the Cellomics ArrayScan VTI platform (Thermo Scientific, Pittsburgh,
USA). A 10x objective was used to collect 10 image fields per well with the filter set XF93.
Hoechst staining allows to quantify the number of cells and to evaluate nuclear condensation
as result of cells injury. In the presence of reactive oxygen species (ROS), DHE dye is oxidised
to fluorescent ethidium which intercalates into DNA; the fluorescent signal is used as a mea-
sure of oxidative stress. Mitochondrial damage was measured using TMRE dye. TMRE is posi-
tively charged and accumulates in active mitochondria due to their negative charge.
Depolarised or damaged mitochondria have decreased membrane potential and fail to retain
TMRE dye. Disruption of the plasma membrane was measured using TOTO-3 dye. TOTO-3 is
a dead cell indicator. Only in case of plasma membrane damage it can penetrate and bind
DNA. ER tracker is a cell permeant fluorescent dye, highly selective for the endoplasmic reticu-
lum. Changes in ER fluorescence intensity can be associated to modification in the ER status.
Fluo-4 was used to measure the increase in cytoplasmic calcium, a common pathophysiological
event in cellular toxicity. Fluo-4 is a cell permeant calcium indicator dye. It binds to calcium
and increases its fluorescent signal. All the fluorescent signals were quantified using the Target
Activation Bioapplication v.4 from Cellomics Scan Software.
Data analysis
All experiments were performed in triplicates. The data were presented as mean ± SEM. Statis-
tical analysis was performed using GraphPad Prism version 5.1. The raw response data for cell
viability and that generated by the Target Activation Bioapplication for the 6 cellular toxicity
endpoints (nuclear condensation, ROS formation, mitochondrial damage, plasma membrane
disruption, ER status, and calcium accumulation) were analysed using GraphPad Prism to gen-
erate dose response curves. Raw data were initially normalised to percent of maximum re-
sponse and then plotted against the logarithmic of tested concentrations using nonlinear
regression sigmoidal dose-response (variable slope) curve fitting. EC50 values were then calcu-
lated for each endpoint being analysed and reported in Table 2 and Table 3. In order to see if
the best-fit value of LogEC50 differs between the three experimental groups (M vs 3F vs 4F),
we used the F test as comparison method. This test selects the simpler model unless the extra
sum-of-squares F test has a P value less than 0.05. The F test compares independent fits with a
global fit that shares the same LogEC50. Moreover, statistical comparison between the fitted
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midpoints (LogEC50) of two curves (3F vs 4F, M vs 4F, and M vs 3F) was performed using the
F test to verify whether the two curves are statistically different with respect to the LogEC50.
Comparison between three groups or two groups of data were considered statistically signifi-
cant when P value<0.05.
Results
Drug selection
To test whether significant differences exist in vitro between human female and male hepato-
cytes, we selected five drugs with varying mechanisms of toxicity and documented sex-related
differences in their adverse effects: Diclofenac, Chlorpromazine, Acetaminophen, Verapamil,
and Omeprazole [34] [35] [22].
Diclofenac is an anti-inflammatory drug acting through cyclooxygenase (COX) inhibition.
Diclofenac is metabolised in the liver by two main pathways: acyl glucuronidation (catalysed
primarily by uridine 5'-diphosphoglucuronosyl transferase 2B7) and phenyl hydroxylation
(catalysed by cytochrome 2C9 and 3A4). The three main metabolites are: Diclofenac glucuro-
nide, 4’-Hydroxy Diclofenac, and 5-Hydroxy Diclofenac [36]. Diclofenac-induced hepatocyte
injury is typically associated with an acute hepatitis-like histology involving necrosis, in some
cases mixed hepatocellular cholestatic injury (cholestatic hepatitis), and mediated by acyl glu-
curonide covalent binding with cellular proteins, oxidative stress, mitochondrial permeability
transition and mitochondrial damage [37] [38]. Additionally, an immuno-allergic component
plays a key role in the liver toxicity of this drug [39]. There is greater susceptibility for Diclofe-
nac related liver injury among women than men [40]. According to DrugCite, reported cases
of adverse effects were 57% women and 36% men (7% unknown sex) with an average age of 57
Table 2. EC50 values for cell viability.
Time EC50 (uM) P value
M 3F 4F M vs 3F vs 4F 3F vs 4F M vs 4F M vs 3F
D
ic
lo
fe
n
ac 5h 676.70 694.70 752.40 0.2023 0.2500 0.0613 0.6715
2h 671.10 757.40 702.70 0.2724 0.3689 0.4436 0.1266
30 min 707.80 713 701.90 0.9846 0.8737 0.9061 0.9361
C
h
lo
rp
ro
m
az
in
e 5h 36.97 36.14 39.54 0.3004 0.1519 0.3157 0.6753
2h 61.89 72.30 66.94 0.0967 0.3032 0.3082 0.0129
30 min 100.60 111.10 80.87 0.0430 0.0193 0.1065 0.3540
A
ce
ta
m
in
o
p
h
en 5h 14.07 18.22 11.74 0.0002 0.0001 0.1058 0.0189
2h 17.91 19.30 16.68 0.0963 0.0494 0.2587 0.2603
30 min 21.59 21.51 20.51 0.8302 0.6492 0.5563 0.9700
V
er
ap
am
il 5h 147.40 143.10 135.10 0.4252 0.3816 0.2272 0.6518
2h 168.30 180.70 151.90 0.2705 0.1134 0.3720 0.4721
30 min 214.40 150.90 157.40 < 0.0001 0.6113 0.0005 < 0.0001
P value< 0.05 are reported in bold and italic.
doi:10.1371/journal.pone.0122786.t002
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Table 3. EC50 values for toxicity parameters.
Time EC50 (uM) P value
M 4F 3F M vs 3F vs 4F 3F vs 4F M vs 4F M vs 3F
D
ic
lo
fe
n
ac
Ca 5h 4.12 6.04 37.57 0.2105 0.6568 0.9507 0.1142
ER 4h 227.70 1031 250.90 0.0251 0.0134 0.1192 0.8834
TOTO3 3h 28.76 67.43 74.81 0.7071 0.9206 0.4603 0.4326
TMRE 3h 839.90 542.70 716.90 0.0061 0.0399 0.0020 0.1755
ROS 3h 431.60 83554 1762 < 0.0001 0.3029 < 0.0001 0.0003
ER 2h 59.24 339.30 597.90 < 0.0001 0.4995 < 0.0001 0.0030
TOTO3 1h 1056 1559 1511 0.8923 0.9946 0.9083 0.6617
TMRE 1h 1430 1597 1465 0.7430 0.6169 0.4572 0.8697
ROS 30 min 1182 1628 1175 0.0004 0.0002 0.0077 0.9579
C
h
lo
rp
ro
m
az
in
e
Ca 5h - - - - - - -
ER 4h 4.43 9.38 8.06 0.0031 0.5677 0.0017 0.0346
TOTO3 3h 186.30 141 164.30 0.0124 0.0610 0.0082 0.1597
TMRE 3h 36.12 22.82 56.12 0.0395 0.0127 0.2471 0.0395
ROS 3h - - - - - - -
ER 2h 5.90 16.93 8.07 0.0217 0.0842 0.0067 0.4305
TOTO3 1h 495.50 61.98 1333 0.0089 0.0045 0.074 0.7624
TMRE 1h 90.23 79.76 237.20 0.2801 0.2322 0.8799 0.1879
ROS 30 min 1.42 0.12 0.32 0.5681 0.7186 0.3023 0.5094
A
ce
ta
m
in
o
p
h
en
Ca 5h 0.76 0.65 0.77 0.9968 0.9503 0.9381 0.9859
ER 5h 0.72 387.90 63.27 < 0.0001 0.5111 0.0001 < 0.0001
TOTO3 4h 0.54 1.34 1.39 0.0002 0.8973 0.0018 0.0020
TMRE 4h 10.80 2.12 26.92 < 0.0001 < 0.0001 0.0001 0.0632
ROS 3h 0.71 0.70 3.44 0.8314 0.529 0.9903 0.6924
ER 2h 17.59 26.92 28.16 0.3134 0.9244 0.2694 0.114
TOTO3 1h 13.72 167.80 19.20 0.0205 0.0601 0.005 0.5354
TMRE 1h 2.64 1.37 3.88 0.0475 0.0092 0.0824 0.3416
ROS 30 min 46.67 25.15 22.36 0.0474 0.6031 0.0328 0.1283
V
er
ap
am
il
Ca 6h - - - - - - -
ER 5h - - - - - - -
TOTO3 5h 617.20 425.30 681 0.2581 0.1268 0.1268 0.7627
TMRE 5h 223.90 104.40 181.10 0.0005 0.0013 0.0048 0.0045
ROS 4h - - - - - - -
ER 3h - - - - - - -
TOTO3 2h 1252 936.90 667.10 0.0292 0.0314 0.3175 0.0117
TMRE 2h 555.80 611.60 557.50 0.9045 0.4088 0.7712 0.9965
ROS 30 min 859.30 1518 1738 0.0040 0.7594 0.0021
O
m
ep
ra
zo
le
Ca 5h 9.41 45.57 56.77 0.2160 0.8578 0.1725 0.2187
ER 4h 754.60 186.90 185.40 0.1681 0.9732 0.1397 0.0771
TOTO3 3h 3855 695 539.10 0.6500 0.8649 0.5460 0.3027
TMRE 3h 356.20 343.40 490.10 0.9464 0.8233 0.9789 0.7693
ROS 3h 0.29 0.23 0.67 0.9279 0.8559 0.9635 0.6711
ER 2h 140.70 245.50 148.90 0.1889 0.4453 0.0445 0.9164
TMRE 1h 16.40 19.07 178.60 0.4699 0.2915 0.8590 0.2200
TOTO3 1h - - - - - - -
ROS 30 min - - - - - - -
P value< 0.05 are reported in bold and italic.
-: EC50 value could not be calculated.
doi:10.1371/journal.pone.0122786.t003
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years [41]. In 180 patients reporting Diclofenac related hepatotoxicity, 79% of cases were fe-
male and 71% of them were over 60 years of age [34]. Reported risk factors for non-steroidal
anti-inflammatory drug-related hepatotoxicity in general, and especially for Diclofenac, in-
clude female sex and age above 50 years [35] [34] [42].
Acetaminophen is metabolically oxidised by cytochrome 2E1 to form a quinone imine me-
tabolite (NAPQI), which traps cellular thiols, both protein and glutathione, by formation of co-
valent adducts. Acetaminophen-induced liver toxicity is characterised by apoptosis, necrosis,
inflammation, and oxidative stress with the latter being the salient feature in this pathogenic
process [43] [44] [45]. According to DrugCite, reported cases of adverse effects were 51%
women and 32% men (17% unknown sex) [46]. A prospective study of acute liver failure at 17
tertiary care centres in the United States has shown that 73% of the patients were women and
Acetaminophen overdose was the most common apparent cause of acute liver failure, account-
ing for 39% of all cases [22].
Chlorpromazine is a tricyclic aliphatic phenothiazine which acts by postsynaptic inhibition
of dopamine receptors that formerly was the most common cause of drug-induced liver injury
in the United States [47]. Chlorpromazine is activated by oxidation to electrophilic species that
disrupt mitochondrial function and form adducts with cellular thiols. Approximately 10 to 12
major metabolites have been identified. The major metabolites are the monoglucuronide of
N-Dedimethyl Chlorpromazine and 7-Hydroxy Chlorpromazine.
Besides being cytotoxic, Chlorpromazine induces mitochondrial injury, cholestasis, and
phospholipidosis [48]. There is likely also a hypersensitivity component causing liver injury.
According to DrugCite, reported cases of adverse effects in September 2013 were 64% women
and 27% men (9% unknown sex), while the latest statistics (September 2014) show 43% female,
47% male, and 10% unknown sex cases [49].
Verapamil is a phenyl-alkylamine class of calcium channel blockers that may cause im-
mune-mediated, inflammatory liver injury (hepatitis) [50]. Verapamil is subject to extensive
oxidative metabolism mediated by cytochrome P450 enzymes. Furthermore, Verapamil is
known to be a potent inhibitor of P-glycoprotein function. Major metabolites are Norverapa-
mil, N-Dealkyl Norverapamil (D620), N-Dealkyl Verapamil (D617) and O-Desmethyl Verapa-
mil (D-703) [51]. According to DrugCite, reported cases of adverse effects were 46% women
and 33% men (21% unknown sex) with an average age of 58 years [52].
Omeprazole is a selective proton pump inhibitor acting by specific inhibition of the hydro-
gen-potassium adenosine-triphosphatase (H+, K+-ATPase) enzyme system at the secretory
surface of parietal cells. Omeprazole is completely metabolised by the cytochrome P450 system
to two major metabolites, 5-hydroxyomeprazole (cytochrome 2C19) and Omeprazole Sulfone
(cytochrome 3A4) [53].
Adverse liver effects typically show acute centrilobular necrosis [54]. The mechanism of he-
patic injury is still unknown. Statistics show that females were adversely affected in 52% and
males in 45% of cases (3% unknown sex) with an age maximum for all groups of 59 years [55].
As a negative control for our study, the non-hepatotoxic compound Caffeine was selected.
Caffeine is a xanthine alkaloid that is metabolised in the liver by cytochrome P450 (1A2 iso-
zyme) into three dimethylxanthines.
ATPmeasurement
Male (M), pre-menopausal female (3F), and post-menopausal female (4F) pooled primary he-
patocytes derived from 12 donors per group were exposed to 8 increasing concentrations
(using a dilution factor of 1:2) of Diclofenac (from 13.6 to 1750 uM), Chlorpromazine (from
1.9 to 250 uM), Acetaminophen (from 0.3 to 35 uM), Verapamil (from 7.8 to 1000 uM),
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Omeprazole (from 1.9 to 250 uM), and Caffeine (from 39 to 5000 uM). Cell survival after 30
min, 2h, and 5h exposure was assayed by CellTiter-Glo. Dose response curves showing a de-
crease in ATP levels at increasing concentration of drugs were obtained for Diclofenac, Chlor-
promazine, Acetaminophen, and Verapamil at each of the tested time points (Fig. 1). EC50
values were calculated and reported in Table 2. Statistically significant differences between the
three groups tested were observed only at certain time points: 30 min exposure to Chlorproma-
zine (P value = 0.043), 30 min treatment with Verapamil (P value<0.0001), and 5h treatment
Fig 1. Cell viability curves for Diclofenac, Chlorpromazine, Acetaminophen, and Verapamil. 5000 human primary hepatocytes pooled from either 12
male donors (M), or 12 pre-menopausal female donors (3F), or 12 post-menopausal female donors (4F) were seeded in 96 well plates and exposed to 8
serial concentrations (using a dilution factor of 1:2) of Diclofenac (from 13.6 to 1750 uM), Chlorpromazine (from 1.9 to 250 uM), Acetaminophen (from 0.3 to
35 uM), or Verapamil (from 7.8 to 1000 uM). Decrease in cell number after 30 min, 2h, or 5h exposure to drugs was assessed by lysing the cells with CellTiter-
Glo Reagent and measuring the ATP levels released. Assays were run in triplicates. Results are expressed as mean ±SEM. Dose response curves were
plotted using GraphPad Prism.
doi:10.1371/journal.pone.0122786.g001
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with Acetaminophen (P value = 0.0002). In particular, Verapamil (30 min) was more toxic in
4F and 3F, with no statistically significant differences between pre and post-menopausal fe-
males (3F vs 4F P value = 0.6113) (Table 2). Chlorpromazine (30 min) and Acetaminophen
(5h) were instead more toxic in 4F and M compared to 3F hepatocytes. Although not statisti-
cally significant differences were observed between 4F and M for Chlorpromazine (30 min)
and Acetaminophen (5h) treatment, postmenopausal cells (4F) viability measurements re-
sulted in a lower EC50 value than that recorded for male cells: 80.87 uM (vs 100.6 uM in Chlor-
promazine treated male) and 11.74 uM (vs 14.07 uM in Acetaminophen treated male)
respectively (Table 2).
Caffeine, a non-hepatotoxic compound, and Omeprazole showed no effect on cell viability
at the tested concentrations and exposure times measured (Fig. 2).
High Content Images
We investigated the mechanisms underlying the cytotoxic effects of Diclofenac, Chlorproma-
zine, Acetaminophen, Verapamil, and Omeprazole by measuring changes in nuclear intensity
(Hoechst 33342 dye), ROS accumulation (DHE dye), mitochondrial damage (TMRE dye),
plasma membrane permeability modification (TOTO3 dye), calcium accumulation (Fluo-4
dye), and endoplasmic reticulum status (ER tracker red) in pooled primary hepatocytes. In
order to capture the main mechanism of toxicity, ROS accumulation was measured at two
early time points: 30 min and 3h, whereas calcium accumulation was assayed at late exposure
time (5h). Mitochondrial membrane potential as marker for mitochondrial injury (at 1h and
3h) and endoplasmic reticulum status (at 2h and 4h) were measured alternating every 2 hours.
Fluorescently stained live cells were imaged using the Cellomics ArrayScan VTI platform and
fluorescence intensities were determined for all tested dyes using the Target Activation Bioap-
plication v.4 from Cellomics Scan Software. As shown in the representative fluorescence
Fig 2. Cell viability curves for Omeprazole and Caffeine. 5000 human primary hepatocytes pooled from either 12 male donors (M), or 12 pre-menopausal
female donors (3F), or 12 post-menopausal female donors (4F) were seeded in 96 well plates and exposed to 8 serial concentrations (using a dilution factor
of 1:2) of Omeprazole (from 1.9 to 250 uM), or Caffeine (from 39 to 5000 uM). Cell viability after 30 min, 2h, or 5h exposure to drugs was assessed by lysing
the cells with CellTiter-Glo Reagent and measuring the ATP levels released. Assays were run in triplicates. Results are expressed as mean ±SEM. Data
were plotted using GraphPad Prism.
doi:10.1371/journal.pone.0122786.g002
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images reported in Fig. 3, hepatotoxic drugs induced formation of reactive oxygen species (in-
creased red signal in 30 min, 1750 uM Diclofenac, Fig. 3 H-J-I compared to untreated G-I-K),
induced variation of the mitochondrial membrane potential (decreased red signal in 3h, 125
uM Chlorpromazine, Fig. 3 B-D-F compared to untreated A-C-E), increased plasma mem-
brane permeability (increased green signal in 3h, 125 uM Chlorpromazine, Fig. 3 B-D-F com-
pared to untreated A-C-E), increased ER intensity (increased red signal in 5h, 0.78 uM
Acetaminophen, Fig. 3 N-P-R compared to untreated M-O-Q), and induced accumulation of
calcium (increased green signal in 5h, 250 uM Omeprazole, Fig. 3 T-V-X compared to untreat-
ed S-U-W) in male and pre/post-menopausal female. M, 3F, and 4F Caffeine treated cells were
used as negative control. Caffeine treated pooled hepatocytes were stained with all the above
markers and some representative images for TMRE-TOTO3 (S1 Fig., b-d-f), DHE (S1 Fig., h-j-
l), ER (S1 Fig., n-p-r), and Fluo-4 (S1 Fig., t-v-x), are reported in S1 Fig.
Nuclear intensity assessment
The effect of each of the five chemicals and Caffeine on nuclear intensity was determined by
staining the nuclei of primary hepatocytes with Hoechst 33342, then imaging, and quantifying
the fluorescent signal. A dose dependent increase in nuclear intensity is often associated with
nuclear condensation as result of cell injury. When primary hepatocytes were treated with
Diclofenac, Verapamil, Acetaminophen, Chlorpromazine, and Omeprazole an increase in nu-
clear intensity was observed for the three groups tested (Fig. 4). Comparing the EC50 values
from the three groups of cells (M vs 3F vs 4F) a P value<0.05 was obtained only after 4h treat-
ment with Diclofenac (P value = 0.0090) and 4h with Verapamil (P value = 0.0144). At 4h,
both Diclofenac and Verapamil resulted to be more toxic in post-menopausal female hepato-
cytes (Fig. 4). No sex differences in terms of nuclear intensity were observed at the other time
points tested (30 min, 1h, 2h, 3h, and 5h). No statistically significant nuclear intensity modifi-
cations were obtained comparing M, 3F, and 4F hepatocytes at any of the tested exposure times
for Acetaminophen (P value = 0.7471 at 4h), Chlorpromazine (P value = 0.6578 at 4h), Omep-
razole (P value = 0.7574 at 4h), and Caffeine.
Reactive Oxygen Species formation
Reactive oxygen species are chemically reactive molecules containing oxygen. They are a natu-
ral by-product of the normal oxygen metabolism, but when increased and persistent they may
result in significant cell damage known as oxidative stress. In primary hepatocytes treated with
Acetaminophen for 30 min, we found that ROS, measured using DHE, accumulated in female
cells (3F EC50 = 22.36 uM, 4F EC50 = 25.15 uM, M EC50 = 46.67 uM) at slightly significantly
lower concentration than in male cells (P value = 0.0474) (Table 3 and Fig. 5). The opposite
was observed in 30 min Verapamil treated hepatocytes where ROS formation occurs in male
hepatocytes (3F EC50 = 1738 uM, 4F EC50 = 1518 uM, M EC50 = 859.3 uM) at significantly
lower concentration than in female cells (P value = 0.0040) (Table 3 and Fig. 5). Moreover, in
primary hepatocytes exposed to Diclofenac for 30 min (Fig. 3 H-J-I), we observed that ROS for-
mation was induced at statistically higher concentration in post-menopausal female (3F
Fig 3. Fluorescence images of human primary hepatocytes. 5000 untreated and treated primary hepatocytes derived fromM, 3F, and 4F donors were
stained for 30 min using Hoechst 33342 and either TMRE and TOTO3 (a-f), or DHE (g-l), or ER tracker red (m-r), or Fluo-4 (s-x) dyes and imaged using the
Cellomics ArrayScan VTI. A 10x objective was used to collect 10 images per well with the filter set XF93. Primary hepatocytes treated for 3h with 125 uM
Chlorpromazine or untreated and stained with Hoechst 33342 (blue), TMRE (red), and TOTO3 (green) are reported in a-f. Primary hepatocytes treated with
1750 uM Diclofenac for 30 min or untreated and stained with Hoechst 33342 (blue) and DHE (red) are reported in g-l. Primary hepatocytes treated for 5h with
0.78 uM Acetaminophen or untreated and stained with Hoechst 33342 (blue) and ER tracker (red) are reported in m-r. Primary hepatocytes treated for 5h with
250 uMOmeprazole or untreated and stained with Hoechst 33342 (blue) and Fluo-4 (green) are reported in s-x.
doi:10.1371/journal.pone.0122786.g003
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EC50 = 1175 uM, 4F EC50 = 1628 uM, M EC50 = 1182 uM) compared to male and pre-meno-
pausal female (P value = 0.0004) (Table 3 and Fig. 5). At the tested concentrations and expo-
sure times, no statistically significant differences in ROS accumulation were observed between
male and female primary hepatocytes treated with Omeprazole and Chlorpromazine (Table 3).
ROS was not accumulated in primary hepatocytes exposed to Caffeine (S1 Fig.).
Mitochondrial damage
The mitochondrial permeability and the loss of mitochondrial membrane potential with subse-
quent release of pro-apoptotic proteins from the inner membrane space into the cytosol, and
decreased ATP production are hallmarks of cell death [56]. To investigate the involvement of
mitochondria in the cytotoxic effects of Diclofenac, Chlorpromazine, Acetaminophen, Verapa-
mil, and Omeprazole, the variation of mitochondrial membrane potential was measured in live
treated primary hepatocytes using TMRE dye. As shown in Fig. 5 and Table 3, for the majority
of the tested chemicals, mitochondrial damage was induced at lower concentrations in post-
menopausal females compared to pre-menopausal females and males. 4F samples exposed to
Diclofenac for 3h had an EC50 = 542.7 uM which is significantly lower (P value = 0.0061) than
the EC50 values obtained for 3F (716.90 uM) and M (839.90 uM). Statistically significant lower
EC50 values were also obtained when post-menopausal females were treated with Chlorproma-
zine for 3h (4F EC50 = 22.82 uM vs 3F EC50 = 56.12 uM vs M EC50 = 36.12 uM; P
value = 0.0395), Acetaminophen for 4h (4F EC50 = 2.12 uM vs 3F EC50 = 26.92 uM vs M
EC50 = 10.80 uM; P value<0.0001), and Verapamil for 5h (4F EC50 = 104.40 uM vs 3F
Fig 4. Nuclear intensity dose response curves after 4h treatment with Diclofenac, Verapamil, Caffeine, Acetaminophen, Chlorpromazine, and
Omeprazole. 5000 human primary hepatocytes pooled from either 12 male donors (M), or 12 pre-menopausal female donors (3F) or 12 post-menopausal
female donors (4F) were seeded in 96 well plates and exposed to 8 serial concentrations (using a dilution factor of 1:2) of Diclofenac (from 13.6 to 1750 uM),
Acetaminophen (from 0.3 to 35 uM), Verapamil (from 7.8 to 1000 uM), Chlorpromazine (from 1.9 to 250 uM), Caffeine (from 39 to 5000 uM), or Omeprazole
(from 1.9 to 250 uM) for 30 min, 1h, 2h, 3h, 4h, and 5h. Hepatocytes nuclei were stained with Hoechst 33342 and increase in nuclear intensity was measured
at different time points using the Cellomics ArrayScan VTI platform and the Target Activation Bioapplication v.4. GraphPad Prism-derived dose response
curves obtained treating primary hepatocytes for 4h with Diclofenac, Verapamil, Acetaminophen, Chlorpromazine, and Omeprazole are reported. Statistically
significant sex differences (P value<0.05) comparing the EC50 values from the three groups of hepatocytes (M vs 3F vs 4F) were observed only with primary
hepatocytes treated for 4h with Diclofenac (P value = 0.0090) or with Verapamil (P value = 0.0144). Diclofenac and Verapamil resulted more toxic in 4F
hepatocytes. No statistically significant nuclear intensity modifications were obtained comparing M, 3F, and 4F hepatocytes treated with Acetaminophen (P
value = 0.7471), Chlorpromazine (P value = 0.6578), and Omeprazole (P value = 0.7574). Caffeine did not give any increase in nuclear intensity. Assays
were run in triplicates. Results are expressed as mean ±SEM.
doi:10.1371/journal.pone.0122786.g004
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EC50 = 181.1 uM vs M EC50 = 223.9 uM; P value = 0.0005) (Table 3). For Omeprazole-treated
hepatocytes, no statistically significant differences between the three tested groups of cells were
observed in terms of mitochondrial toxicity (Table 3). Mitochondrial membrane potential was
not changed in primary hepatocytes treated with Caffeine (S1 Fig., b-d-f).
Endoplasmic reticulum status
The endoplasmic reticulum is involved in several important functions such as the folding of se-
cretory and membrane proteins. Various conditions including toxic effects such as exposure to
free radicals, can cause pathological accumulation of unfolded proteins in the ER, a condition
referred to as ER stress. ER-stress induces dilatation of ER-membranes and other alterations
in ER-appearance [57] [58]. We measured ER morphological changes by staining primary
Fig 5. Cytotoxicity dose response curves. 5000 human primary hepatocytes pooled from either 12 male donors (M), or 12 pre-menopausal female donors
(3F), or 12 post-menopausal female donors (4F) were seeded in 96 well plates and exposed to 8 serial concentrations of Diclofenac (from 13.6 to 1750 uM),
Chlorpromazine (from 1.9 to 250 uM), Acetaminophen (from 0.3 to 35 uM), and Verapamil (from 7.8 to 1000 uM). ROS formation (DHE dye), endoplasmic
reticulum status (ER tracker red dye), mitochondrial damage (TMRE dye), and plasmamembrane permeability (TOTO3 dye) were measured at different time
points (30 min, 2h, 3h, 4h, 5h) using the Cellomics ArrayScan VTI platform and the Target Activation Bioapplication v.4. Representative dose-response
curves are shown for drugs having a P value<0.05 (M vs 3F vs 4F) in Table 3 (Diclofenac, Chlorpromazine, Acetaminophen, and Verapamil). Three
replicates were tested and represented using GraphPad Prism. Results are expressed as mean ±SEM.
doi:10.1371/journal.pone.0122786.g005
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human hepatocytes with ER tracker red dye and quantifying the increase in ER-signal using
fluorescence microscopy imaging of live cells. Dose response curves for ER intensity showed
that male hepatocytes exposed for 2h to either Diclofenac (M EC50 = 59.24 uM vs 4F
EC50 = 339.3 uM vs 3F EC50 = 597.9 uM; P value<0.0001) or Chlorpromazine (M EC50 = 5.9
uM vs 4F EC50 = 16.93 uM vs 3F EC50 = 8.07 uM; P value = 0.0217), or treated for 5h with
Acetaminophen (M EC50 = 0.72 uM vs 4F EC50 = 387.9 uM vs 3F EC50 = 63.27 uM; P
value<0.0001) are significantly more sensitive to ER modification than pre- and post-meno-
pausal female cells (Table 3 and Fig. 5). No statistically significant differences in terms of ER
modifications were found in cells treated with Verapamil, Omeprazole, and Caffeine (Table 3
and S1 Fig., n-p-r).
Plasma Membrane permeability
Cell membrane integrity is a well-known and common indicator of cell viability. Loss of mem-
brane integrity was measured by quantifying the cellular influx of TOTO3 dye. In terms of
plasma membrane permeability, statistically significant differences between the three groups
were observed for Chlorpromazine, Acetaminophen, and Verapamil treated hepatocytes
(Fig. 5). Cells treatment with Chlorpromazine for 3h induces plasma membrane damage at
statistically lower concentration (4F EC50 = 141 uM vs 3F EC50 = 164.3 uM vs M EC50 =
186.3 uM; P value = 0.0124) in post-menopausal female hepatocytes confirming the data ob-
tained by mitochondrial damage (Table 3). After 4h, Acetaminophen-treated male hepatocytes
membrane disruption was induced at lower concentration (M EC50 = 0.54 uM vs 4F EC50 =
1.34 uM vs 3F EC50 = 1.39 uM; P value = 0.0002) compared to pre-and post-menopausal fe-
male cells. In accordance with the toxicity data obtained by staining hepatocytes with TMRE
(5h), plasma membrane damage in female cells treated with Verapamil for 2h was induced at a
lower concentration than in male samples (M EC50 = 1252 uM vs 4F EC50 = 936.9 uM vs 3F
EC50 = 667.1 uM; P value = 0.0292). No statistically significant sex-differences measured as
plasma membrane permeability were observed at any time point for Diclofenac, Omeprazole,
and Caffeine (Table 3 and S1 Fig., b-d-f).
Accumulation of intracellular calcium
Loss of calcium homeostasis with increased intracellular calcium level results from failure of
energy dependent Ca++—Mg++ ATPase pump and it is also related to increased membrane per-
meability and cell mediated death. Calcium accumulation was measured in treated primary he-
patocytes using Fluo-4 dye and EC50 values were obtained for Diclofenac, Chlorpromazine,
Acetaminophen, and Omeprazole without finding any statistically significant differences be-
tween the three groups of cells tested (Table 3). Calcium was not accumulated in primary hepa-
tocytes treated with Verapamil (Table 3) and Caffeine (S1 Fig., t-v-x).
Discussion
Clinical and epidemiological data showing sex-related differences in drug-induced liver injury
are well documented and, in general, a higher susceptibility in females is reported in the litera-
ture [22] [59] [21] [60] [61] [26] [62] [20] [63] [64] [42]. Basic research as well as risk assess-
ment and clinical trials (in which women are still less enrolled and sex-specific analysis is
usually not included in the results evaluation) are mainly done with males, be it from human
volunteers, animals, or cell culture [7] [8] [65] [12].
This study aimed to investigate whether cellular reactions to drugs with well-known hepato-
toxic effects differ between male and female human hepatocytes. Multiple parameters
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measured by high content imaging were used to determine sex differences in toxicity at a
molecular level.
To overcome human individual genetic variability, we decided to use primary human hepa-
tocytes pooled from 12 donors as a cellular model. Male and female pooled hepatocytes, which
are solely available in suspension, were tested in cell-based assays. Female hepatocytes were fur-
ther sub-classified into pre- and post-menopausal groups to account for women’s hormonal
age-related changes. The age dependence of adverse effects is also reflected in clinical statistics
[61] [34] [42] [26].
The three groups of human hepatocytes were exposed for a maximum of 6 hours (because
of the limited life-span of hepatocytes in suspension) to five hepatotoxic drugs: Diclofenac,
Chlorpromazine, Acetaminophen, Verapamil, and Omeprazole. These drugs have different
mechanisms of toxicity and well documented sex-related differences in their adverse effects
[34] [35] [22]. They are metabolised in the liver and, apart from Verapamil which has an idio-
syncratic mechanism, their hepatotoxic effect is partly attributed to adduct formation. Hepatic
injury driven by these drugs is characterised by: oxidative stress, mitochondrial dysfunction,
cholestasis, phospholipidosis, and hepatitis. Moreover a non-hepatotoxic substance, Caffeine,
was tested as negative control.
Previous studies of cytochrome P450 substrates for sex-dependent differences in pharmaco-
kinetic parameters have shown inconsistent results. In our experiments, we did not check for
drug metabolites to account for any differences in metabolism, although this would be an inter-
esting addition in future studies to understand how the metabolism of these drugs contributes
to differences in hepatotoxic effects.
ATP measurement showed statistically significant differences between male and females
only when hepatocytes were treated for 30 min with Chlorpromazine, for 5h with Acetamino-
phen, and for 30 min with Verapamil. Sex differences in cell viability were not observed for the
rest of the drugs and exposure times. In order to look into the mechanisms of drug toxicity,
ROS formation, mitochondrial damage, endoplasmic reticulum modification, plasma mem-
brane permeability, and calcium accumulation were measured at different time points. Dose re-
sponse curves were obtained for most of the selected exposure times and, for certain
parameters and specific drugs, statistically significant differences were observed between the
three groups of hepatocytes tested.
Mitochondrial damage was measured in vitro as variation of the mitochondrial membrane
potential. Our data showed that post-menopausal female hepatocytes exposed to either Diclo-
fenac, or Acetaminophen, or Chlorpromazine, or Verapamil are more sensitive to mitochon-
drial damage than pre-menopausal female and male cells. These data are consistent with
clinical findings showing that women are experiencing more adverse drug reactions than men
and that this risk is increasing with age [26]. In women, the incidence rates of hepatic adverse
drug reactions increase after menopause and this is especially valid for nonsteroidal anti-in-
flammatory drugs such as Diclofenac [34] [42] [35].
Moreover, progressive deterioration of mitochondrial function in postmenopausal woman
has been described in various contexts [66] [67] and this could explain why most of the tested
drugs showed greater toxicity in 4F cells.
In vivo, sex-related differences in hepatic mitochondrial function have been studied in rats
and mice without showing a consistent sex-specific pattern, but rather depending on species
and tissue [68] [69]. Liver mitochondria from female rats have been shown to have higher lev-
els of reduced glutathione, higher protein content, higher cardiolipin levels, greater respiratory
and phosphorylative capacities, more-energised mitochondria and to generate half the amount
of peroxides than those from males [70] [68]. In mice however, no differences between males
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and females have been found when analysing key parameters for mitochondrial bioenergetics,
oxidative stress, and apoptosis [71].
Endoplasmic reticulum status was evaluated by staining the ER and measuring its morpho-
logical changes using image quantification. For this parameter, our data showed that male he-
patocytes exposed to either Diclofenac, or Acetaminophen, or Chlorpromazine are more
sensitive to ER modifications compared to female hepatocytes. Sex differences in ER status
were previously reported in some in vivo studies. For instance, it has been shown that kidneys
of male mice are much more susceptible to ER stress-induced acute kidney injury than those of
females [72] and that under pressure-overload condition male mice are more vulnerable to ER
stress than female mice [73]. This effect has not been described in human hepatocytes before.
At first sight, our ER status data seem conflicting with the mitochondrial toxicity results, for
which female cells showed higher sensitivity. A reasonable explanation could lie in the fact that
ER morphology does not necessarily correlate with ER stress, it is a coping mechanism that
does not always indicate stress. Induction of phospholipid biosynthetic enzymes generate new
membranes, thereby increasing the volume of the ER, simultaneously diluting unfolded pro-
teins, and preparing the compartment to receive an influx of newly synthesised folding factors
[74]. Thus, increasing ER size through membrane synthesis is an integral yet distinct part of
the cellular programme to overcome ER stress [75].
Disturbances in the normal functions of the ER lead to an evolutionarily well conserved cell
stress response, the unfolded protein response (UPR), which is aimed initially at compensating
for damage but can eventually trigger cell death if ER dysfunction is severe or prolonged ER
stress involves triggering of both the “alarm” and the “adaptive” phase responses. The adaptive
(protective) phase leads to the up-regulation of ER chaperone proteins which assist in the re-
folding of proteins, relieve ER stress, and re-establish normal ER function. The initial intent of
the UPR is to adapt to the changing environment, and re-establish normal ER function [76].
Faced with persistent ER stress, adaptation starts to fail and apoptosis occurs [77]. Our data
pose new questions which should be studied further to understand the differences in response
to insult between sexes.
Peyrou and Cribb [78] have demonstrated that induction of ER stress proteins following a
prior ER stress (‘‘ER stress preconditioning”) resulted in decreased toxicity of several model
toxins and ER stress preconditioning therefore offers cytoprotection against clinically relevant
nephrotoxins in renal cell lines from multiple species. Therefore we could speculate that the in-
crease in ER intensity, observed as more pronounced in male cells, is a sign for increased pro-
tein folding, corresponded to "positive" ER preconditioning rather than to "negative" ER stress
effects. Gene expression studies could provide a further insight into sex differences but were
not within the scope of this study.
In correlation with the hypothesis that female hepatocytes are more sensitive to hepatotoxi-
cant damage, we observed that in terms of nuclear condensation, Verapamil and Diclofenac
are more toxic in the post-menopausal female group. Moreover for substances such as Verapa-
mil and Chlorpromazine we showed that the plasma membrane permeability—an indicator for
cell death—is more compromised in female hepatocytes than male cells. Acetaminophen treat-
ment also showed that reactive oxygen species accumulation is occurring in female hepatocytes
at lower concentration than in male cells. For cells treated with Diclofenac and Verapamil for
30 min, we instead observed that male hepatocytes have a statistically significant increase in
ROS, though longer exposure to the same drugs induced mitochondrial damage mainly in fe-
male hepatocytes. Therefore, we hypothesise that male hepatocytes might be able to overcome
the toxic insult induced by Diclofenac and Verapamil by increasing the intracellular level of
ROS [79] [80].
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For calcium accumulation no statistically significant differences between the three groups at
the testing concentrations and exposure times was observed. This is probably due to the short
observation period of our experiments.
To our knowledge this was the first attempt to compare in vitro reactions to toxicants be-
tween human male and female (pre- and post-menopausal) primary hepatocytes. Research in
this field so far has been performed either in vivo with animal studies or in vitro with primary
cells from animals or human immortalised cell-lines [8] [65] [7] [81] [82] [24] [27] [83] [84].
This study is the first step to elucidate cell-based sex differences in response to toxicants and
the molecular pathways affected. Further experiments are needed to confirm our results and
extend evidence for these observations. Some practical difficulties also have to be tackled such
as the short life-span of primary hepatocytes in suspension. The time frame chosen is suitable
for acute, high dose effects in vitro, but longer exposure times will be needed to detect more sig-
nificant or long-term pathological differences between sexes. Six hours is a too short for the
emergence of hepatotoxic endpoints such as steatosis. Furthermore, the differences that have
been observed at early time points could become more significant after longer exposure times
or in repeated dose experiments. In future experiments a broader choice of drugs might give a
more comprehensive picture of differing cellular processes between male and female-derived
cells. Similarly, it might be interesting to elucidate the inter-individual differences within each
group by studying the responses of hepatocytes derived from single donors.
Conclusions
In conclusion, this work presents an attempt to detect sex-based differences in cellular reac-
tions to toxicants by using a human-relevant model in vitro, namely primary human hepato-
cytes pooled from different donor groups. Considering the fundamental difference in the
genome of male and female cells it could be assumed that the cells themselves might show dif-
ferent sex-specific behaviour when exposed to toxic compounds, although detailed specific dif-
ferences have not been demonstrated yet.
Our experiments showed significant differences in mitochondrial injury, nuclear condensa-
tion, ER status, and plasma membrane permeability between sexes presenting female cells as
being more sensitive, at certain exposure times, for some of the tested drugs.
Moreover, our work demonstrated that high content screening and analysis is feasible with
pooled primary human hepatocytes in suspension and such research might not only yield
deeper insight into the effects of the karyotype of our basic structural and functional unit of
life, but also contribute to more accurate screening methods for risk assessment that consider
the varying susceptibility of male and female populations. We conclude that more focused re-
search and data are still needed to increase evidence for male/female differences and similari-
ties in response to toxicants, and that whenever possible, in vitro and in vivo studies should
analyse data by sex to give a sex-specific report of scientific results.
Supporting Information
S1 Fig. Fluorescence images of Caffeine treated human primary hepatocytes. 5000 untreated
and Caffeine treated primary hepatocytes derived from M, 3F, and 4F donors were stained for
30 min using Hoechst 33342 and either TMRE and TOTO3 (a-f), or DHE (g-l), or ER tracker
red (m-r), or Fluo-4 (s-x) dyes and imaged using the Cellomics ArrayScan VTI. A 10x objective
was used to collect 10 images per well with the filter set XF93. Primary hepatocytes treated for
3h with 625 uM Caffeine or untreated and stained with Hoechst 33342 (blue), TMRE (red),
and TOTO3 (green) are reported in a-f. Primary hepatocytes treated with 1250 uM Caffeine
for 30 min or untreated and stained with Hoechst 33342 (blue) and DHE (red) are reported in
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g-l. Primary hepatocytes treated for 4h with 625 uM Caffeine or untreated and stained with
Hoechst 33342 (blue) and ER tracker (red) are reported in m-r. Primary hepatocytes treated
for 5h with 625 uM Caffeine or untreated and stained with Hoechst 33342 (blue) and Fluo-4
(green) are reported in s-x.
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